Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens-Reference-Cited by-同舟云学术

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Published:2019-04 Issue:7753 Volume:568 Page:511-516
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Behan Fiona M.,Iorio Francesco,Picco Gabriele,Gonçalves Emanuel,Beaver Charlotte M.,Migliardi Giorgia,Santos Rita,Rao Yanhua,Sassi Francesco,Pinnelli Marika,Ansari Rizwan,Harper Sarah,Jackson David Adam,McRae Rebecca,Pooley Rachel,Wilkinson Piers,van der Meer Dieudonne,Dow David,Buser-Doepner Carolyn,Bertotti Andrea,Trusolino Livio,Stronach Euan A.,Saez-Rodriguez Julio,Yusa Kosuke,Garnett Mathew J.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-019-1103-9.pdf

Reference47 articles.

1. Garraway, L. A. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31, 1806–1814 (2013).

2. Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).

3. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51 (2014).

4. Koike-Yusa, H., Li, Y., Tan, E.-P., Del Castillo Velasco-Herrera, M. & Yusa, K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR–guide RNA library. Nat. Biotechnol. 32, 267–273 (2014).

5. Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).

Cited by 966 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SERPINA3 is a marker of cartilage differentiation and is essential for the expression of extracellular matrix genes during early chondrogenesis;Matrix Biology;2024-11

2. Chemical coverage of human biological pathways;Drug Discovery Today;2024-10

3. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma;Gut;2024-09-11

4. Genetic engineering in oncology based on CRISPR-Cas9 technology;Siberian journal of oncology;2024-09-09

5. PROTAC-mediated conditional degradation of the WRN helicase as a potential strategy for selective killing of cancer cells with microsatellite instability;Scientific Reports;2024-09-06